What is the Arrowhead Pharmaceuticals Inc. stock price forecast?

Arrowhead Pharmaceuticals Inc. is currently trading at $79.14. View real-time AI analysis on Alpha Lenz.

What is Arrowhead Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Arrowhead Pharmaceuticals Inc. on Alpha Lenz.

What is Arrowhead Pharmaceuticals Inc.'s P/E ratio?

Arrowhead Pharmaceuticals Inc.'s P/E ratio is -6490.3.

Arrowhead Pharmaceuticals Inc.

NASDAQ · ARWR

$79.14+4.21(+5.62%)Market closed

Ask about Arrowhead Pharmaceuticals Inc.'s future dividend policy...

Alpha Chat Insight

“Arrowhead Pharmaceuticals Inc. trades at a P/E of -6490.3 (undervalued) with modest ROE of -0.5%. 3Y revenue CAGR of 50.5% highlights clear growth momentum.”

Ask for details →

Company Overview

Arrowhead Pharmaceuticals Inc. is a biotechnology company actively engaged in the development of innovative medicines. Its primary focus is on leveraging its proprietary technology platform to create novel therapeutics based on gene silencing mechanisms. This approach involves designing drugs that can selectively interfere with the expression of disease-causing genes. Arrowhead Pharmaceuticals is particularly focused on diseases that have limited treatment options, utilizing RNA interference (RNAi) technology to develop treatments for conditions such as chronic hepatitis B, alpha-1 antitrypsin deficiency, and cardiovascular disease. By targeting the genetic roots of these illnesses, the company aims to provide more effective and lasting therapeutic solutions. Operating within the dynamic biotechnology sector, Arrowhead Pharmaceuticals is a key player in the advancement of precision medicine and personalized treatment strategies. Its contributions not only address unmet medical needs but also exemplify the potential of RNAi technology in transforming healthcare outcomes. As part of the broader pharmaceutical and biotech industry, Arrowhead Pharmaceuticals holds a significant position in pushing the frontiers of medical innovation.

CEODr. Christopher R. Anzalone Ph.D.

Websitehttps://arrowheadpharma.com

SectorHealthcare

IndustryBiotechnology

Employees609

Company Statistics

FY 2025

Profile

$10.59BMarket Cap

$829.45MRevenue

0.00Shares Out

609Employees

Margins

N/AGross

19.87%EBITDA

11.86%Operating

6.21%Pre-Tax

3.63%Net

Valuation

-6490.26P/E

22.71P/B

12.76EV/Sales

66.14EV/EBITDA

67.47P/FCF

Growth (CAGR)

50.52%Rev 3Yr

56.63%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

2.39%ROA

-0.50%ROE

11.16%ROIC

Financial Health

$88.71MCash & Cash Equivalents

$793.17MNet Debt

175.18%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Arrowhead Pharmaceuticals Inc. trades at a P/E of -6490.3 (undervalued) with modest ROE of -0.5%. 3Y revenue CAGR of 50.5% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Arrowhead Pharmaceuticals Inc. (ticker: ARWR) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 609 employees. Market cap is $10.6B.

The current price is $79.14 with a P/E ratio of -6,490.26x and P/B of 22.71x.

ROE is -0.50% and operating margin is 11.86%. Annual revenue is $829M.